Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Conditions
Keywords
Atopic dermatitis, Eczema, Skin Diseases, Eczematous, Netherton syndrome, Skin Diseases, Genetic, BPR277
Brief summary
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to evaluate safety and efficacy in atopic dermatitis (Part 2) and in Netherton syndrome (Part 3).
Interventions
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Part 1 Healthy volunteers * Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health Part 2 Patients with atopic dermatitis: * Male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations * Presence of atopic dermatitis confirmed by Itchy skin condition in the past 12 months (must have) Plus three or more of the following: 1. History of involvement of the skin creases 2. Personal history of asthma or hay fever 3. History of generally dry skin in the past year 4. Onset before age of 2 years 5. Visible flexural dermatitis * Diagnosis of at least moderate atopic dermatitis by the IGA and a minimum target area (right or left) situated on the forearm including the antecubital fossa with a corresponding baseline total lesional sign score (TLSS) Part 3 Patients with Netherton Syndrome: * Patients with Netherton syndrome, male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations * Confirmed diagnosis of Netherton syndrome (SPINK5 mutation or LEKTI deficiency in the skin). * Minimum total lesional sign score NS (TLSS-NS) of 5-9 for two selected target areas at baseline. The TLSS-NS values need to be similar between the two areas at baseline.
Exclusion criteria
Part 1 Healthy volunteers : * History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction. * Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. Part 2 Patients with atopic dermatitis: * History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction. * History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds. * Pregnant or nursing (lactating) women. * Women of child-bearing potential must use highly effective contraception (as further defined in study protocol) * Use of topical prescription treatment for eczema within 1 week prior to initial dosing of topical corticosteroids (TCS). * Recent previous treatment with systemic treatment including phototherapy. A washout period will be required for such patients to be eligible to participate in the trial. Part 3 Patients with Netherton Syndrome: * History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction. * History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds. * Pregnant or nursing (lactating) women. * Women of child-bearing potential must use highly effective contraception (as further defined in study protocol) * Use of topical prescription treatment within 2 week prior to initial dosing of study drug. * Recent previous treatment with systemic treatment. A washout period will be required for such patients to be eligible to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systemic and local tolerability of BPR277 ointment, as measured by change in local tolerability score, number of adverse events and clinically significant changes in standard hematology, blood chemistry. | 2-4 weeks |
| Part 2 and 3: Patients with Atopic Dermatitis / Netherton syndrome: Change in Total Lesional Signs Score at the treated skin area | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Part 2 and 3: Patients with Atopic Dermatitis / Netherton syndrome: Change for each sign comprising the total lesional signs score at the treated skin area | 4 weeks |
Countries
Netherlands, United States
Outcome results
None listed